title: Carbimazole embryopathy: an emerging phenotype.
abstract: Concerns about the safety of carbimazole in pregnancy were raised in 1985. Since this time many reports of children believed to have been affected by carbimazole in utero have appeared in the medical literature. Initial reports were of an increased incidence of scalp defects in the infants of treated mothers, but many other anomalies have now been described. Choanal atresia, gastrointestinal anomalies-particularly esophageal atresia, athelia/hypothelia, developmental delay, hearing loss, and dysmorphic facial features have all been reported. The phenotype associated with exposure to carbimazole appears to be rare but specific with distinctive facial features. We report on two new cases of carbimazole embryopathy with strikingly similar facial features.
authors.affiliation: SW Thames Regional Genetics Services, St. George's Hospital, London, UK. nfoulds@sghms.ac.uk
authors.forename: Nicola
authors.initials: N
authors.lastname: Foulds
authors.forename: Ian
authors.initials: I
authors.lastname: Walpole
authors.forename: Frances
authors.initials: F
authors.lastname: Elmslie
authors.forename: Sahar
authors.initials: S
authors.lastname: Mansour
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000473:pathology; D000293:Adolescent; D013956:Antithyroid Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002231:Carbimazole / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004423:Ear / Q000002:abnormalities; D005138:Eyebrows / Q000002:abnormalities; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy; D009666:Nose / Q000002:abnormalities; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D013971:Thyrotoxicosis / Q000188:drug therapy
chemical_list: D013956:Antithyroid Agents; D002231:Carbimazole